- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03261570
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
Orthostatic intolerance is defined by debilitating upright symptoms that are relieved by sitting or lying. Symptoms include upright lightheadedness, fatigue, confusion, and decreased memory called 'Brain Fog' by patients. The most common chronic form is Postural Tachycardia Syndrome (POTS), characterized by excessive upright tachycardia without hypotension. Of note, >85% of POTS patients are female. The proposal that Brain Fog was caused by reduced cerebral blood flow (CBF) has been disproven, because graded incremental upright tilt failed to demonstrate difference in mean CBF compared to healthy volunteers. Nevertheless, memory task performance deteriorates with angle of tilt as does task-related neurovascular coupling (NVC), which links neural activity to an increase in CBF known as "functional hyperemia". The investigators have previously observed that large low frequency (0.07-0.13 Hz) oscillations in BP (OBP), which entrained and amplified oscillations in CBF (OCBF), increased with tilt angle and were associated with impaired working memory and reduced functional hyperemia.
The sympathetic baroreflex remains intact and HR is excessively increased in the absence of parasympathetic counterregulation. The cardiovagal baroreflex couples BP to HR to buffer BP changes. Large low frequency BP oscillations, representing a resonance within the sympathetic baroreflex loop, occur if there is central hypovolemia, an intact sympathetic baroreflex, and reduced parasympathetic buffering of BP by HR; conditions found in upright POTS. This leads to the following hypothetical paradigm:
↓Cardiovagal Baroreflex → ↑OBP → ↑↑OCBF → ↓NVC → ↓working memory. Therefore, in this application, the investigators hypothesize that the cardiovagal baroreflex is impaired in POTS while supine, becomes further impaired with orthostasis, and accounts for OBP, OCBF, and loss of NVC. Further, the investigators propose that improving the cardiovagal baroreflex improves hemodynamics and Brain Fog in POTS patients.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Hawthorne, New York, United States, 10532
- New York Medical College/Bradhurst building
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for POTS patients:
POTS patients referred for day to day orthostatic intolerance with greater than 3 symptoms for greater than 3 months and will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test :
- dizziness
- nausea and vomiting
- palpitations
- fatigue
- headache
- exercise intolerance
- blurred vision
- abnormal sweating heat.
Healthy control subjects:
- normal physical examination, and normal electrocardiographic and echocardiographic evaluations.
- Only those free from heart disease, and from systemic illness will be eligible to participate.
- This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease.
At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks.
Exclusion Criteria for both POTS and healthy controls:
- An active medical condition that may explain the diagnosis
- A previous medical condition with undocumented resolution that may explain the diagnosis
- any systemic or overt structural, arrhythmic or myopathic cardiovascular disease
- any illnesses known to produce autonomic dysfunction such as diabetes, heart disease, renal disease, systemic hypertension, acute and chronic inflammatory diseases, neoplastic disease, immune mediated disease, major trauma and burns, morbid obesity and peripheral vascular disease will also be excluded.
- Cigarette smokers will be excluded.
- Past or present major psychiatric disorder
- Substance abuse within 2 years before onset of symptoms.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pyridostigmine and Placebo
Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
|
60mg by mouth
Other Names:
Lactulose 50mg by mouth
|
Active Comparator: Digoxin and Placebo
Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
|
Lactulose 50mg by mouth
0.5 (500mcg) by mouth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovagal Baroreflex during orthostatic stress
Time Frame: 1 year
|
Cardiovagal Baroreflex during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt.
The unmedicated baroreflex measurement will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin.
Baroreflex measurements will be obtained using the standard "modified Oxford" technique.
|
1 year
|
Cognitive ability during orthostatic stress
Time Frame: 1 year
|
. Cognitive ability during orthostatic stress in unmedicated POTS patients compared to unmedicated control subjects during each angle of incremental tilt.
Cognitive ability will be repeated in POTS patients to similar measurements after treatment with placebo, pyridostigmine or digoxin.
Cognitive ability will be assessed with a standard 2-Back test in which patients identify identical alphabetic characters appearing 2 characters before the current displayed character in a sequence of 29 characters.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac output measure by inert gas breathing technique
Time Frame: 1 year
|
Cardiac output measure by inert gas breathing technique.
Cardiac output is the amount of blood pumped by the heart in one minute.
The technique uses the Innocor system in which the relative levels of two inert gases - one blood soluble and one insoluble component - are measured over a few respirations (about 5 breaths or 15 seconds).
The rate of disappearance of the soluble gas from the alveolar space is proportional to the flow of blood perfusing the lungs and equals the cardiac output.
|
1 year
|
Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle
Time Frame: 1 year
|
Arterial blood pressure in mmHg over each cardiac cycle will be collected using finger photoplethysmography.
The arterial pressure is reported as an aggregate of 3 extracted quantities: the systolic blood pressure which is the maximum blood pressure over a cardiac cycle; the diastolic blood pressure which is the minimum blood pressure over a cardiac cycle; and the mean blood pressure which is the average blood pressure over a cardiac cycle.
|
1 year
|
Heart rate
Time Frame: 1 year
|
1 year
|
|
systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Julian M. Stewart, M.D., Ph.D., New York Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Disease
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Syndrome
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Orthostatic Intolerance
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Protective Agents
- Cardiotonic Agents
- Cholinesterase Inhibitors
- Digoxin
- Pyridostigmine Bromide
Other Study ID Numbers
- 1R01HL134674-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Orthostatic Intolerance
-
Rigshospitalet, DenmarkCompletedPostoperative Orthostatic Hypotension | Postoperative Orthostatic IntoleranceDenmark
-
National Institute of Neurological Disorders and...Completed
-
ShireCompletedSymptomatic Orthostatic HypotensionUnited States, Poland, Czechia, Slovakia
-
James J. Peters Veterans Affairs Medical CenterCompleted
-
Seoul National University HospitalCompletedOrthostatic; Hypotension, NeurogenicKorea, Republic of
-
H. Lundbeck A/SCompletedSymptomatic Neurogenic Orthostatic HypotensionUnited States
-
Hackensack Meridian HealthWithdrawnNeurogenic Orthostatic HypotensionUnited States
-
Seoul National University HospitalKyung Hee University Hospital at GangdongCompletedNeurogenic Orthostatic HypotensionKorea, Republic of
-
Isotech LtdNewcastle-upon-Tyne Hospitals NHS TrustRecruitingOrthostatic HypotensionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompleted
Clinical Trials on Pyridostigmine
-
UMC UtrechtCompletedSpinal Muscular Atrophy | SMA | Kugelberg-Welander DiseaseNetherlands
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedDiabetes Mellitus | Constipation | Gastric Emptying | Colonic TransitUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPostural Tachycardia SyndromeUnited States
-
Ain Shams UniversityCompletedPostdural Puncture HeadacheEgypt
-
Hospital de Clinicas de Porto AlegreCompletedDiabetes ComplicationsBrazil
-
University of MiamiAmerican Diabetes AssociationCompleted
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
University of AarhusAarhus University HospitalUnknownMyasthenia GravisDenmark
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHIV | Non-HIV | Vagus Nerve DysfunctionUnited States